ID: ALA3971045

Max Phase: Preclinical

Molecular Formula: C19H20N6O2

Molecular Weight: 364.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  CN(C)Cc1cc2c(nc1C=O)N(C(=O)Nc1ccc(C#N)cn1)CCC2

Standard InChI:  InChI=1S/C19H20N6O2/c1-24(2)11-15-8-14-4-3-7-25(18(14)22-16(15)12-26)19(27)23-17-6-5-13(9-20)10-21-17/h5-6,8,10,12H,3-4,7,11H2,1-2H3,(H,21,23,27)

Standard InChI Key:  VRSRHEKCWDTVRL-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 364.41

Molecular Weight (Monoisotopic): 364.1648

AlogP: 2.21

#Rotatable Bonds: 4

Polar Surface Area: 102.22

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.95

CX Basic pKa: 6.84

CX LogP: 2.41

CX LogD: 2.30

Aromatic Rings: 2

Heavy Atoms: 27

QED Weighted: 0.83

Np Likeness Score: -1.62

References

1.  (2016)  Ring-fused bicyclic pyridyl derivatives as FGFR4 inhibitors, 

2. Fairhurst RA,Knoepfel T,Buschmann N,Leblanc C,Mah R,Todorov M,Nimsgern P,Ripoche S,Niklaus M,Warin N,Luu VH,Madoerin M,Wirth J,Graus-Porta D,Weiss A,Kiffe M,Wartmann M,Kinyamu-Akunda J,Sterker D,Stamm C,Adler F,Buhles A,Schadt H,Couttet P,Blank J,Galuba I,Trappe J,Voshol J,Ostermann N,Zou C,Berghausen J,Del Rio Espinola A,Jahnke W,Furet P.  (2020)  Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4.,  63  (21.0): [PMID:32930584] [10.1021/acs.jmedchem.0c01019]

Source

Source(2):

• Scientific Literature
• BindingDB Database